Carrie Schinstock, MD
Nephrology · Rochester, MNNPI 1881703734
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,594 of the $6,184 with a category attached, or 90.5%. CSL Behring accounts for 97.6% of it on its own, with 1 other manufacturer making up the rest.
Across 5 payments — averaging $1236.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$6K
- AstraZeneca$150
Across 208 payments — averaging $2314.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$481K
What the payments were for
- Consulting fees$5,59490%
- Speaking & faculty fees$1502%
- Food & beverage$4417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 4 | $6,034 |
| AstraZeneca | 1 | $150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$150
How this compares
$6,184 in reported general payments places this provider in the 85th percentile of 208 nephrology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 23 | $5,677 |
| Valganciclovir Hcl | 23 | $3,916 |
| Tacrolimus | 25 | $2,196 |
| Prednisone | 63 | $404 |
| Rosuvastatin Calcium | 21 | $258 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 44 | $245 |
| Amlodipine Besylate | 44 | $231 |
| Lisinopril | 12 | $191 |
| Pantoprazole Sodium | 23 | $155 |
| Carvedilol | 32 | $130 |
| Losartan Potassium | 28 | $111 |
| Tamsulosin Hcl | 12 | $106 |
| Alendronate Sodium | 12 | $92 |
| Atorvastatin Calcium | 25 | $91 |
| Metoprolol Tartrate | 16 | $82 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Rochester
- Neera DahlRochester$102K
- Fernando FervenzaRochester$102K
- Nelson LeungRochester$32K
- John LieskeRochester$31K
- Leticia RolonRochester$30K
- Nattawat KlomjitRochester$25K
- Ladan ZandRochester$25K
- Marie HoganRochester$19K
- Kianoush Banaei KashaniRochester$19K
- Aleksandra KuklaRochester$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.